Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global HIV drugs market reached a value of US$ 26.4 Billion in 2020. Looking forward, IMARC Group expects the market to reach a value of US$ 32.9 Billion by 2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global HIV Drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on class and distribution channel.

Breakup by Class:

  • Nucleoside Reverse Transcriptase Inhibitors 
  • Multi-Class Combination Products 
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors 
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist 
  • Fusion Inhibitors and Others
     

Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
     

On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.

Regional Insights:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
     

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson 
  • Merck.
     

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.

Report Coverage:

Report Features Details
Base Year of the Analysis 2020
Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Class, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global HIV Drugs Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Price Analysis
    5.5    Market Breakup by Drug Class
    5.6    Market Breakup by Distribution Channel
    5.7    Market Breakup by Region
    5.8    Market Forecast
    5.9    SWOT Analysis
        5.9.1    Overview
        5.9.2    Strengths
        5.9.3    Weaknesses
        5.9.4    Opportunities
        5.9.5    Threats
    5.10    Value Chain Analysis
        5.10.1    Overview
        5.10.2    Research and Development
        5.10.3    Raw Material Procurement
        5.10.4    Manufacturing
        5.10.5    Marketing
        5.10.6    Distribution
        5.10.7    End-Use
    5.11    Porters Five Forces Analysis
        5.11.1    Overview
        5.11.2    Bargaining Power of Buyers
        5.11.3    Bargaining Power of Suppliers
        5.11.4    Degree of Competition
        5.11.5    Threat of New Entrants
        5.11.6    Threat of Substitutes
6    Market Breakup by Drug Class
    6.1    Nucleoside Reverse Transcriptase Inhibitors 
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Multi-Class Combination Products 
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Protease Inhibitors
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    HIV Integrase Strand Transfer Inhibitors 
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Non-Nucleoside Reverse Transcriptase Inhibitors 
        6.5.1 Market Trends
        6.5.2 Market Forecast
    6.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist 
        6.6.1 Market Trends
        6.6.2 Market Forecast
    6.7    Fusion Inhibitors and Others
        6.7.1 Market Trends
        6.7.2 Market Forecast
7    Market Breakup by Distribution Channel
    7.1    Hospital Pharmacies
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Retail Pharmacies
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Online Pharmacies
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Others
        7.4.1 Market Trends
        7.4.2 Market Forecast
8    Market Breakup by Region
    8.1    North America
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Europe
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Asia Pacific
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Middle East and Africa
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Latin America
        8.5.1 Market Trends
        8.5.2 Market Forecast
9    HIV Drugs Manufacturing Process
    9.1    Product Overview
    9.2    Raw Material Requirements
    9.3    Manufacturing Process
    9.4    Key Success and Risk Factors
10    Competitive Landscape
    10.1    Market Structure
    10.2    Market Breakup by Key Players
    10.3    Profiles of Key Players
        10.3.1    Boehringer Ingelheim International GmbH
        10.3.2    Merck & Co., Inc. 
        10.3.3    ViiV Healthcare
        10.3.4    AbbVie
        10.3.5    F. Hoffmann-La Roche Ltd. 
        10.3.6    Teva Pharmaceutical Industries Ltd. 
        10.3.7    Bristol-Myers Squibb 
        10.3.8    Gilead Sciences, Inc. 
        10.3.9    Johnson & Johnson
        10.3.10    Cipla Limited 
        10.3.11    Daiichi Sankyo 
        10.3.12    Emcure 
        10.3.13    Hetero Drugs 
        10.3.14    Mylan

List of Figures

Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2020
Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2020
Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2020
Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 7: Global: HIV Drugs Industry: SWOT Analysis
Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
Figure 9: Global: HIV Drugs Industry: Porter’s Five Forces Analysis
Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2015 & 2020
Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 20: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2015 & 2020
Figure 21: Global: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2015 & 2020
Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2021-2026
Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2015 & 2020
Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2021-2026
Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2015 & 2020
Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2021-2026
Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 5: HIV Drugs Manufacturing: Raw Material Requirements
Table 6: Global: HIV Drugs Market: Competitive Structure
Table 7: Global: HIV Drugs Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Question Answered in this Report

The global HIV drugs market reached a value of US$ 26.4 Billion in 2020.

According to the estimates by IMARC Group, the global HIV drugs market is expected to exhibit moderate growth during the next five years.

The increasing prevalence of HIV and its diagnosis represents one of the key drivers for the global HIV drugs market.

The introduction of generic drugs that are cost-effective and chemically-identical to branded drugs represents one of the key trends in the global HIV drugs market.

Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations and state of emergency across several nations resulting in disrupted supply chains for HIV drugs. 

On the basis of the class, the market has been bifurcated into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist, and HIV integrase strand transfer inhibitors. Amongst these, nucleoside reverse transcriptase inhibitors hold the majority of the total market share.

On the basis of the distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, online pharmacies, and others. At present, hospital pharmacies exhibit a clear dominance in the market.

Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links